Advancing MEK-Directed Strategies in Metastatic Pancreatic Cancer

Image by Ashling Wahner & MJH Life Sciences Using AI

MAPKeeper-301 Aims to Confirm the Efficacy of Atebimetinib in Metastatic Pancreatic Cancer

August 31st 2026

The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.

Atebimetinib and Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Image Credit: © Image by Ashling Wahner & MJH Life Sciences Using AI

Dr Ahn on Phase 2a Data With Atebimetinib and Chemotherapy in Pancreatic Cancer

ByDaniel H. Ahn, DO

June 18th 2026

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

First-Line Metastatic PDAC ©: Sebastian Kaulitzki - stock.adobe.com

Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel Shows Encouraging Efficacy, Tolerability in First-Line Metastatic PDAC

ByCourtney Flaherty

June 1st 2026

The novel MEK1/2 inhibitor produced an ORR of 36% and a median OS of 17.3 months in all-comers, supporting its advancement in the phase 3 MAPKeeper 301 trial.